ArticleThe Journal of bone and joint surgery. American volume2020
Surgical Outcome and Oncological Survival of Osteofibrous Dysplasia-Like and Classic Adamantinomas: An International Multicenter Study of 318 Cases.
Article in The Journal of bone and joint surgery. American volume, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Management of Tibial Adamantinoma: Balancing Oncologic Cure and Reconstructive Longevity.Cureus · 2026Review
- Adamantinoma of Bone: A Structured Narrative Review of Clinical Outcomes, Recurrence Patterns, and Metastatic Behaviour.Reports (MDPI) · 2026Review
- [Primary malignant bone tumours-part II].Radiologie (Heidelberg, Germany) · 2026Review
- Treatment and Management of Osteofibrous Dysplasia Like Adamantinoma - A Single Institution Experience.Journal of the Pediatric Orthopaedic Society of North America · 2026Article
- Osteofibrous dysplasia (OFD) and adamantinoma: A comprehensive review and updates.Histology and histopathology · 2026Review
- Motorized Intramedullary Bone Transport Nail for Reconstruction of a Large Diaphyseal Bone Defect after Tumor Resection in a Child-A Case Report.Children (Basel, Switzerland) · 2025Article
- Osteofibrous dysplasia, osteofibrous Dysplasia-Like adamantinoma, and adamantinoma: A Single-center retrospective analysis.Journal of bone oncology · 2025Article
- UK guidelines for the management of bone sarcomas.British journal of cancer · 2025Review
- Adamantinoma: A SEER-based Epidemiological Analysis.Indian journal of surgical oncology · 2024Article
- Osteofibrous dysplasia: a narrative review.Journal of orthopaedic surgery and research · 2024Review
- Adamantinoma: A review of the current literature.Journal of bone oncology · 2023Review
- Update of pediatric bone tumors-other mesenchymal tumors of bone, hematopoietic neoplasms of bone, and WHO classification of undifferentiated small round cell sarcomas of bone.Skeletal radiology · 2023Review
- [Primary malignant bone tumors].Orthopadie (Heidelberg, Germany) · 2023Article
- Osteofibrous dysplasia-like adamantinoma of isolated fibula in a child mimicking chronic osteomyelitis with pathological fracture.Journal of surgical case reports · 2022Article
- Rapidly Progressive Classic Adamantinoma of the Spine: Case Report and Literature Review.Frontiers in oncology · 2022Article
- Recurrent Adamantinoma With Fibrous Dysplasia-like Feature.Clinical pathology (Thousand Oaks, Ventura County, Calif.)Article
- Adamantinoma: An Updated Review.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundOsteofibrous dysplasia-like adamantinoma (OFD-AD) and classic adamantinoma (AD) are rare, neoplastic diseases with only limited data supporting current treatment protocols. We believe that our retrospective multicenter cohort study is the largest analysis of patients with adamantinoma to date. The primary purpose of this study was to describe the disease characteristics and evaluate the oncological outcomes. The secondary purpose was to identify risk factors for local recurrence after surgical treatment and propose treatment guidelines.
methodsThree hundred and eighteen confirmed cases of OFD-AD and AD for which primary treatment was carried out between 1985 and 2015 were submitted by 22 tertiary bone tumor centers. Proposed clinical risk factors for local recurrence such as size, type, and margins were analyzed using univariable and multivariate Cox regression analysis.
resultsOf the 318 cases, 128 were OFD-AD and 190 were AD. The mean age at diagnosis was 17 years (median, 14.5 years) for OFD-AD and 32 years (median, 28 years) for AD; 53% of the patients were female. The mean tumor size in the OFD-AD and AD groups combined was 7.8 cm, measured histologically. Sixteen percent of the patients sustained a pathological fracture prior to treatment. Local recurrence was recorded in 22% of the OFD-AD cases and 24% of the AD cases. None of the recurrences in the OFD-AD group progressed to AD. Metastatic disease was found in 18% of the AD cases and fatal disease, in 11% of the AD cases. No metastatic or fatal disease was reported in the OFD-AD group. Multivariate Cox regression analysis demonstrated that uncontaminated resection margins (hazard ratio [HR] = 0.164, 95% confidence interval [CI] = 0.092 to 0.290, p < 0.001), pathological fracture (HR = 1.968, 95% CI = 1.076 to 3.600, p = 0.028), and sex (female versus male: HR = 0.535, 95% CI = 0.300 to 0.952, p = 0.033) impacted the risk of local recurrence.
conclusionsOFD-AD and AD are parts of a disease spectrum but should be regarded as different entities. Our results support reclassification of OFD-AD into the intermediate locally aggressive category, based on the local recurrence rate of 22% and absence of metastases. In our study, metastatic disease was restricted to the AD group (an 18% rate). We advocate wide resection with uncontaminated margins including bone and involved periosteum for both OFD-AD and AD. LEVEL OF EVIDENCE: Prognostic Level IV. See Instructions for Authors for a complete description of levels of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.